Point72 Middle East Fze Eli Lilly & CO Call Options Transaction History

Point72 Middle East Fze

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$525.19 - $619.13 $2.26 Million - $2.66 Million	4,300 Added 28.29%	19,500 $11.4 Million
Q3 2023 Nov 14, 2023	BUY	$434.7 - $599.3 $6.61 Million - $9.11 Million	15,200 New	15,200 $8.16 Million
Q1 2023 May 15, 2023	BUY	$310.63 - $364.82 $1.99 Million - $2.33 Million	6,400 Added 172.97%	10,100 $3.47 Million
Q4 2022 Feb 14, 2023	BUY	$321.55 - $374.67 $1.19 Million - $1.39 Million	3,700 New	3,700 $0

4,004

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $711B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Point72 Middle East Fze, based on Form 13F filings with the SEC.

Stay updated on Point72 Middle East Fze with notifications on news.